About Axolabs Kulmbach

Axolabs GmbH, Kulmbach, is the world’s leading custom research organization in the field of preclinical and clinical development of DNA-/RNA-based therapeutics. We are committed to providing high-end solutions and consultancy services for the development of innovative drugs. Our expert team has 20+ years of experience in the development of oligonucleotide therapeutics and has access to excellent infrastructure. We are well known, from big-pharma and biotech to academia and venture capital, for our profound knowledge, high quality standards and excellent research. Our broad range of services for therapeutic oligonucleotides and mRNAs covers, in particular, bioinformatics, chemical synthesis of oligonucleotides, oligonucleotide conjugates and formulations, analytics, bioanalytics and in vitro testing. 
Axolabs GmbH is a limited liability corporation wholly owned by the LGC Group.


Our clients

Axolabs counts the majority of research groups in the field of nucleic acid and oligonucleotide-based therapeutics worldwide among its clients, including >20 big pharma enterprises, >250 biotech companies, >30 academic research institutes and venture capital firms. 


Our history

Axolabs Kulmbach was started by Drs Roland Kreutzer and Stefan Limmer under the name of Ribopharma AG in 2000 as the first company in the world to focus on RNAi therapeutics (see Pioneering Discovery). In 2003 Ribopharma AG merged with Alnylam Pharmaceuticals Inc. to create the leading RNAi therapeutics company. In 2007 – in the course of a spin-off from Alnylam Europe AG – Roche Kulmbach GmbH was established as Roche's Center of Excellence for RNA Therapeutics, which focused on the discovery of novel therapeutics based on oligonucleotides. In November 2011 the management bought out the assets from Roche Kulmbach GmbH and established Axolabs GmbH. In March 2017 Axolabs GmbH was acquired by the LGC Group. The founders of Axolabs, Roland Kreutzer, Andreas Bossko and Hans-Peter Vornlocher, left the management board between 2019 and 2022, with Hans-Peter Vornlocher continuing to work in the company as Chief Scientific Officer (CSO).